Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High – What’s Next?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) reached a new 52-week high during trading on Monday . The stock traded as high as $57.20 and last traded at $55.7850, with a volume of 707587 shares. The stock had previously closed at $54.81.

Analysts Set New Price Targets

A number of research firms have issued reports on ELVN. JonesTrading increased their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Guggenheim started coverage on shares of Enliven Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $80.00 price target for the company. Stifel Nicolaus lifted their price target on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Mizuho increased their price objective on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $70.50.

Enliven Therapeutics Price Performance

The company’s fifty day simple moving average is $46.75 and its two-hundred day simple moving average is $38.58. The stock has a market cap of $3.57 billion, a price-to-earnings ratio of -35.02 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.57 earnings per share for the current year.

Insider Activity

In other news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Friday, July 17th. The stock was sold at an average price of $52.64, for a total value of $316,787.52. Following the transaction, the chief financial officer owned 46,054 shares in the company, valued at $2,424,282.56. This trade represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $50.49, for a total value of $504,900.00. Following the transaction, the director directly owned 41,884 shares in the company, valued at approximately $2,114,723.16. The trade was a 19.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 32,036 shares of company stock worth $1,430,676. 3.00% of the stock is owned by insiders.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently bought and sold shares of the company. KBC Group NV bought a new stake in shares of Enliven Therapeutics in the 1st quarter worth $38,000. FNY Investment Advisers LLC purchased a new position in Enliven Therapeutics during the second quarter worth about $126,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the last quarter. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Finally, Quantbot Technologies LP lifted its position in shares of Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after buying an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.